S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling

Pingping Luo\textsuperscript{a,†}, Ming Zheng\textsuperscript{b,†}, Rui Zhang\textsuperscript{a}, Hong Zhang\textsuperscript{b}, Yingxia Liu\textsuperscript{c}, Wei Li\textsuperscript{d}, Xiaoming Sun\textsuperscript{e}, Qian Yu\textsuperscript{f}, George L. Tipoe\textsuperscript{f,*}, Jia Xiao\textsuperscript{a,f,*}

\textsuperscript{a}Clinical Medicine Research Institute, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China
\textsuperscript{b}Department of Interventional Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China
\textsuperscript{c}State Key Discipline of Infectious Diseases, Department of Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518000, China
\textsuperscript{d}Faculty of Pharmaceutical Sciences, Toho University, Chiba 2748510, Japan
\textsuperscript{e}School of Integrative Pharmacy, Institute of Integrative Pharmaceutical Research, Guangdong Pharmaceutical University, Guangzhou 510000, China
\textsuperscript{f}School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong 999077, China

Received 29 June 2020; received in revised form 31 August 2020; accepted 7 September 2020

Abstract

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
SAMC improves ALD partly through insulin receptor signaling

1. Introduction
Alcoholic liver disease (ALD) causes insulin resistance, lipid metabolism dysfunction, and inflammation. We investigated the protective effects and direct regulating target of S-allylmercaptocysteine (SAMC) from aged garlic on liver cell injury. A chronic ethanol-fed ALD in vivo model (the NIAAA model) was used to test the protective functions of SAMC. It was observed that SAMC (300 mg/kg, by gavage method) effectively ameliorated ALD-induced body weight reduction, steatosis, insulin resistance, and inflammation without affecting the health status of the control mice, as demonstrated by histological, biochemical, and molecular biology assays. By using biophysical assays and molecular docking, we demonstrated that SAMC directly targeted insulin receptor (INSR) protein on the cell membrane and then restored downstream IRS-1/AKT/GSK3β signaling. Liver-specific knock-down in mice and siRNA-mediated knock-down in AML-12 cells of Insr significantly impaired SAMC (250 μM in cells)-mediated protection. Restoration of the IRS-1/AKT signaling partly recovered hepatic injury and further contributed to SAMC’s beneficial effects. Continuous administration of AKT agonist and recombinant IGF-1 in combination with SAMC showed hepato-protection in the mice model. Long-term (90-day) administration of SAMC had no obvious adverse effect on healthy mice. We conclude that SAMC is an effective and safe hepato-protective complimentary agent against ALD partly through the direct binding of INSR and partial regulation of the IRS-1/AKT/GSK3β pathway.

Abstract  Alcoholic liver disease (ALD) causes insulin resistance, lipid metabolism dysfunction, and inflammation. We investigated the protective effects and direct regulating target of S-allylmercaptocysteine (SAMC) from aged garlic on liver cell injury. A chronic ethanol-fed ALD in vivo model (the NIAAA model) was used to test the protective functions of SAMC. It was observed that SAMC (300 mg/kg, by gavage method) effectively ameliorated ALD-induced body weight reduction, steatosis, insulin resistance, and inflammation without affecting the health status of the control mice, as demonstrated by histological, biochemical, and molecular biology assays. By using biophysical assays and molecular docking, we demonstrated that SAMC directly targeted insulin receptor (INSR) protein on the cell membrane and then restored downstream IRS-1/AKT/GSK3β signaling. Liver-specific knock-down in mice and siRNA-mediated knock-down in AML-12 cells of Insr significantly impaired SAMC (250 μM in cells)-mediated protection. Restoration of the IRS-1/AKT signaling partly recovered hepatic injury and further contributed to SAMC’s beneficial effects. Continuous administration of AKT agonist and recombinant IGF-1 in combination with SAMC showed hepato-protection in the mice model. Long-term (90-day) administration of SAMC had no obvious adverse effect on healthy mice. We conclude that SAMC is an effective and safe hepato-protective complimentary agent against ALD partly through the direct binding of INSR and partial regulation of the IRS-1/AKT/GSK3β pathway.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2. Materials and methods
2.1. Chemicals and reagents
SAMC powder (>95%) was provided by Wakunaga Pharmaceutical Co., Ltd. (Osaka, Japan). Pure ethanol was purchased from Guangzhou Chemical Reagent Factory (Guangzhou, China). All cell culture consumables and reagents were supplied by either Corning Incorporated (Corning, NY, USA) or Gibco (Carlsbad, CA, USA). Primary antibodies against adiponectin (ADIPOQ; #ab22554), phosphorylated AKT at Thr308 or Ser473 (pAKT; #ab38449 and #ab81283), total AKT (#ab154993), adipose triglyceride lipase (ATGL; #ab109251), phosphorylated adenosine

KEY WORDS
Alcoholic liver disease; S-allylmercaptocysteine; Insulin receptor; Insulin resistance; IRS-1; AKT; GSK3β; Safety
5’-monophosphate (AMP)-activated protein kinase at Ser487 (pAMPK, #ab131375), total AMPK (#ab32047), beta-actin (#ab115777), cleaved caspase-3 (C-caspase-3; #ab2302), carnitine palmityltransferase I (CPT1; #ab128568), cytochrome P450 2E1 (CYP2E1; #ab28146), CD45 (#ab205718), phosphorylated glycogen synthase kinase 3 beta at Ser9 or Tyr216 (pGSK3β; #ab75814 and #ab75745), total GSK3β (#ab32391), nuclear factor erythroid 2-related factor 2 (NRF2; #ab156883), phosphorylated nuclear factor kappa B p65 subunit at Ser536 (pNF-κB p65; #ab86299), total NF-κB P65 (#ab16502), peroxisome proliferator-activated receptor alpha (PPARα; #ab24509), PPARγ (#ab59256), and sterol regulatory element-binding protein 1c (SREBP-1c; #ab28481) were purchased from Abcam (Cambridge, UK). Anti- bodies against phosphorylated hormone sensitive lipase at Ser563 (HSL; #4139), total HSL (#4107), phosphorylated IRS-1 at Ser302 (#2384), and total IRS-1 (#2382) were products of Cell Signaling (Shanghai, China). All antibodies are validated by their manufacturers (see corresponding product web pages) and in our pilot studies. The dilution ratios for all primary antibodies and secondary antibodies used in the current study were 1:1000 and 1:2000, respectively.

2.2. Construction of AAV8-shInsr

AAV was produced by transfection of AAV-293 cells with three plasmids namely an AAV vector expressing the shRNA to mouse Insr, AV helper plasmid (pAAV Helper) and AAV Rep/Cap expression plasmid. After transfection for 72 h, cells were collected and lysed using a freeze-thaw procedure. Viral particles were purified by an iodixanol step-gradient ultracentrifugation method. AAV was concentrated using a 100 kDa molecular-mass cut off ultracentrifugation device. The genomic titer was 2.5 \times 10^{12} \text{ to } 5 \times 10^{12} \text{ infectious units per mL as determined by quantitative PCR. To construct shRNAs, oligo-nucleotides that contained sense and antisense sequences were connected with a hairpin loop followed by a poly (T) termination signal. The sequence of the control shRNA was TTCTCCGAACGTGT-CAGCT. These shRNAs were ligated into an AAV8 vector expressing H1 promoter and EGFP.

2.3. Animals and experimental design

Male C57BL/6 wild-type mice (7-week old; 18–19 g) were purchased from Guangdong Medical Animal Centre (Guangzhou, China). Mice were acclimatized to their environment for 1 week before the experiments. Alcoholic liver injury was induced by using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) model with minor modifications. Briefly, mice (10/group) were initially fed ad libitum with the control Lieber-DeCarli diet for 5 days to allow acclimation to liquid diet. Then, the NIAAA groups (indicated as ‘EtOH’ group in figures) were fed with the Lieber-DeCarli diet containing 5% (v/v) ethanol for 10 days (first stage), while the control mice (indicated as ‘Pair’ group in figures) were pair-fed with the isocaloric control diet (same caloric content). Changes in body weight and food intake of each mouse were recorded every day. On Day 11, ethanol-fed and pair-fed mice were fed by gavage method in the early morning with a single dose of ethanol (the binge consumption; 5 g/kg body weight) or isocaloric maltose dextrin, respectively, and euthanized 9 h later. SAMC (300 mg/kg, in normal saline) regimens also fed by gavage method on Day 6 and administered every other day (indicated as ‘EtOH + SAMC’ group in figures). Pair-fed mice were fed by gavage method with the same volume of SAMC (indicated as ‘Pair + SAMC’ group in figures) or saline. Parallel experiments using N-acetyl-L-cysteine (NAC, 100 mg/kg, gavage, every other day; Sigma–Aldrich, St. Louis, MO, USA; #A9165) \text{, resveratrol (0.0125%, v/v, of total diet, Sigma–} Aldrich; #R5010) \text{, and silibinin (Legalon, SIL, 25 mg/kg, i.p. injection, every other day; Madaus, Cologne, Germany) were also conducted using the same NIAAA model. For viral injections, mice were injected via the tail vein with 1 \times 10^{12} genome copies of AAV8 control or AAV-shRNA (five per group). After 14 days, mice fasted for 4 h at the end of the dark cycle and then sacrificed to ensure the hepatic down-regulation of Insr. These mice were also subjected to NIAAA model and/or SAMC administration as described above. To verify the function of AKT activation, re-combinant human insulin-like growth factor-1 (IGF-1, 100 µg/kg, i.p. injection; Sigma–Aldrich, #I8779) was administered every other day in conjunction with the start of ethanol consumption. For long-term safety test, 300 mg/kg SAMC was administered every day for 90 days. After 90 days, tissues from the liver, heart, kidneys, and spleen were prepared for haematoxylin and eosin (H&E) histological evaluations and biochemical assays. The optimal dose of SAMC (300 mg/kg) was selected based on our previous liver disease studies. All experimental procedures were approved by the Ethical Committee of Shenzhen Third People’s Hospital, Shenzhen, China.

2.4. Serum/hepatic biochemistry and cytokine measurements

Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG) and total cholesterol (TC) were measured using Hitachi LABOSPECT 008 (Hitachi High-Tech Co., Tokyo, Japan). Serum and hepatic cytokine levels were determined by using corresponding ELISA kits from Peprotech [Rocky Hill, NJ, USA; tumor necrosis factor (TNF)-α: #900-M54; IL-6: #900-M50]. Blood ethanol levels were measured 2 h after the binge gavage with the UV photometric method of Boehringer Diagnostica Mannheim GmbH and measured on an automated 717 clinical chemistry analyzer (Hitachi) at a wavelength of 365 nm. Hepatic TG contents were measured by a colorimetric TG assay kit from Sigma–Aldrich (#MAK266).

2.5. Tissue histology

Tissues were fixed in 10% phosphate-buffered formalin and embedded in paraffin blocks. A thickness of 5 µm of tissue section was cut and stained with H&E and oil red O (Sigma–Aldrich) for histological analysis using a LEICA Qwin Image Analyzer (Leica Microsystems Ltd., Milton Keynes, UK). The NAFLD activity score (NAS) of each group was calculated as previously described. For adipose tissue assays, tissues were also fixed in 10% formalin and then cut at 7 µm for H&E staining and quantification. Five tissue sections from each group were selected, and the diameters of 40 adipocytes from each tissue section were measured. For lipolysis assay, epididymal white adipose tissues (WAT) were cut from mice and washed in pre-warmed Dulbecco’s PBS containing 100 U/mL penicillin and 100 mg/mL streptomycin. Connective tissue and blood vessel were removed. After that, 20 mg of adipose tissue explants were placed into 24-well
plates, cut into small pieces, and cultured in 200 μL of Dulbecco's modified Eagle's medium (DMEM). Released free fatty acids were measured by using a commercial kit from BioVision (Milpitas, CA; #K612-100). Immunohistochemistry of CD45 in mice liver sections was conducted by using CD45 antibody (Abcam, 1:5000 dilution; #ab208022) with DAB (Abcam) color development.

2.6. Respiratory exchange ratio and energy expenditure

Respiratory exchange ratio (RER) and energy expenditure were measured by using a Comprehensive Laboratory Animal Monitoring System (Columbus Instruments, Columbus, OH, USA). Four mice per group were housed individually and assessed by indirect calorimetry over 48 h (last 2 days of the NIAAA model) and maintained at 24 °C under at 12-h:12-h light–dark cycle. An RER of 0.7 indicates that fat is the predominant fuel source, while an RER closer to 1.0 indicates that carbohydrate is the primary fuel [30].

2.7. Insulin resistance measurements

A glucose tolerance test (GTT; 2.5 g/kg glucose, i.p. injection) was performed on the 6-h fasted mice (from AM 8:00 to PM 2:00) by using a glucometer from Roche (Accu-Chek Performa, Basel, Switzerland) at blood collecting time points of 0, 30, 60, 90, 120 min (n = 5; extra mice in parallel experiments). For insulin challenge experiments, the mice were i.p. injected with 2 U/kg recombinant insulin (Sigma–Aldrich; #91077C) 20 min before tissue collection. Plasma insulin level was measured using an ELISA kit from BioVision (#K4271) (n = 5; extra mice in parallel experiments).

2.8. Surface plasmon resonance (SPR) and thermal shift assay (TSA)

The possible direct interaction between SAMC and insulin receptor was validated by using both SPR and TSA assays. SPR was conducted at 25 °C on a BIACore T100 SPR instrument (GE Healthcare, Chicago, IL, USA). SPR running buffer contained 50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 3 mmol/L EDTA and 0.005% (v/v) Tween-20 and was prepared immediately before measurement. BIACore sensor chip CMS was activated for 5–10 min in a 1:1 mixture of 0.1 mol/L N-hydroxysuccinimide and 0.1 mol/L N-ethyl-N-(3-diethylaminopropyl)-carbodiimide at a flow rate of 10 μL/min. Recombinant mouse insulin receptor protein (Chinese hamster ovary cell-derived eukaryotic protein, R&D systems, Minneapolis, MN, USA) was immobilized via amine coupling on a flow cell of the chip. The remaining binding sites on the chips were blocked by 1 mol/L ethanolamine (pH 8.5) at a flow rate of 10 μL/min for 5 min. Control sensorgrams, obtained on an empty flow cell where the coupling reaction had been conducted in the presence of coupling buffer alone, were always subtracted from binding responses. SAMC was diluted in the running buffer and then injected at different concentrations (100, 200 and 400 μg/mL) and passed over adjacent target and control flow cells at a flow rate of 20 μL/min for 180 s. After a 5-min dissociation, the bound analytes were removed by a 20-s wash with 20 mmol/L NaOH.

For TSA, we used 0.04 mg/mL insulin receptor protein with or without 0.2 mmol/L of SAMC in PBS. Data were analyzed with the differential scanning fluorimetry analysis tool (Microsoft Excel based) using the curve-fitting software XLfit 5 (www.idbs.com, ID Business Solutions Ltd.).

2.9. Protein structure modelling

To predict the binding properties of SAMC on INSR, we used the crystal structure of INSR:GRB14 complex from Protein Data Bank (PDB) database (PDB code: 2AUH and 2Z8C) since previous studies demonstrated that growth factor receptor-bound protein 14 (GRB14) was a tissue-specific negative regulator of INSR signaling, and the inhibition was mediated by the BPS (between PH and SH2) region [37]. Targeting the insulin receptor tyrosine kinase domain (IRTK)–GRB14 interaction, in order to relieve the GRB14 inhibitory action on the IRTK, has been considered to be a potential therapeutic strategy to improve insulin signaling [38]. The binding pose of compound in the binding site of IRTK was predicted by the Autodock (version 4.2.6; The Scripps Research Institute, La Jolla, CA, USA). Then, the protein and compound were prepared by AutoDockTools software (version 1.5.6; The Scripps Research Institute).

2.10. Cell culture and transfection

The mouse normal hepatocyte line AML-12 was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM with 10% (v/v) fetal bovine serum (FBS) at 37 °C with 5% CO2 using a cell incubator. Cells were treated after they reached a confluence of 60%–70%. To induce in vitro ALD-like injury of AML-12 cells, we co-treated cells with 250 mmol/L ethanol and 0.25 mmol/L palmitate acid (PA; Sigma–Aldrich; #P0500) for 24 h [39]. To investigate the effects of SAMC on AML-12 cells, different doses of SAMC were added along with concurrent PA and ethanol for a 24-h incubation. Of note, since there is no FDA-approved ALD drug and the efficacy of steroids, anti-TNF agents, growth factors, or antioxidants in treating ALD is controversial and heavily depends on disease stage and host conditions [30], we did not set a positive drug to make a comparison with SAMC in the pharmacodynamic experiment. Knockdown of Insr was achieved by transfection of Rosetta Predictions siRNA (Sigma–Aldrich; #NM_010568) with Lipofectamine 3000 reagent (Thermo-Fisher, Waltham, MA; #L3000001). Overexpression of Insr-1 and Akt in AML-12 cells was conducted by using pCDNA3.1 plasmid harboring full-length sequences of open reading frame (ORF) of mouse Insr-1 (NCBI Reference Sequence: NM_010570.4) and Akt 1 (NCBI Reference Sequence: NM_009652.3) with Lipofectamine 3000.

2.11. Cell viability/apoptosis

The 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) cell viability assay was conducted as described in previous report [17]. After drug treatment, Hoechst 33342 (5 μg/mL) and propidium iodide (5 μg/mL) were added to each well to stain live cells. Quantifications of apoptotic ratio and caspase-3/7 activity were conducted as previously described [35].

2.12. Caspase-3/7 activity and P65 activity assay

Activities of caspase-3/7 from cell lysates after treatment were measured using Cell Meter Caspase-3/7 Activity Apoptosis Assay Kit (AAT Bio., Sunnyvale, CA, USA; #22795) according to the
user manual. Final results were read at 520 nm in a micro-plate reader (Bio-Rad) and expressed as fold change in caspase-3/7 activity relative to the control. To test the cellular NF-κB P65 activity, a NF-κB P65 Transcription Factor Assay Kit (Abcam; #ab133112) was used according to user’s instructions.

2.13. Quantitative real-time PCR

Total RNA was extracted from fresh liver tissue samples or cell lysates by using the CellAmp™ Direct RNA Prep Kit (Takara Bio, Inc., Shiga, Japan; #3732). The first strand cDNA was synthesized from total RNA using a PrimeScript™ RT Reagent Kit (Takara; #RR037) following the manufacturer’s instructions. qPCR reaction was performed with the SYBR Premix Taq Quantitative PCR Kit (Takara Bio, Inc.), according to the manufacturer’s instructions, on a MyiQ2 real-time quantitative PCR machine (Bio-Rad, Berkeley, CA, USA). Primer information is as listed in Supporting Information Table S1. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was amplified as an internal control.

The relative quantification of mRNA expression levels was done according to the 2\(^{-ΔΔCt}\) method. All real-time PCR procedures, including the design of primers, validation of PCR environment and quantification methods, were performed according the MIQE guideline\(^{31}\).

2.14. Protein extraction and Western blot

After treatments, cells or liver tissues were washed with sterile phosphate buffer saline (PBS) for three times and then subjected to total protein extraction by using a RIPA kit from Sigma-Aldrich. For secreted protein, culture medium was collected and centrifuged for RIPA extraction. Then protein samples were quantified with BCA reagent from Bio-Rad. Western blot analyses of all proteins were performed as described using β-actin as the internal control.

2.15. In vitro glucose uptake assay

Cell-based glucose uptake assay was conducted by using a commercial kit from Cayman Chemical (Ann Arbor, MI, USA; #10009582) according to manufacturer’s instructions. Briefly, AML12 cells were seeded at 2.5 × 10\(^4\) cells/well in a 96-well plate and incubated overnight. On the next day, cells were treated with ethanol + PA and/or SAMC (250 μmol/L) for 24 h in glucose-free culture medium. Ten minutes before the end of the treatment (half cells were stimulated with 20 nmol/L for 10 min), cells were incubated with 200 μg/mL 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) for 8 h. Culture plates were then centrifuged for 5 min at 400×g at room temperature, and the supernatants were aspirated. Cells were incubated with reaction buffer for 10 min and then the glucose uptake was measured with fluorescent filters (excitation/emission = 485 nm/535 nm).

2.16. TCF/LEF reporter luciferase assay

The activity of β-catenin was measured by a luciferase reporter assay of T-cell factor/lymphoid enhancer factor (TCF/LEF)-dependent transcription with Cignal TCF/LEF Reporter Kit (Qiagen, Valencia, CA, USA). Renilla luciferase construct was also co-transfected into each well for normalization. The luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Fitchburg, WI, USA).

2.17. Statistical analysis

Data were expressed as mean ± standard error of mean (SEM). All data in this study were normally distributed as confirmed by the Shapiro-Wilk test and P–P plot using SPSS software package. Statistical differences for two group comparison were determined using independent-samples t-test (SPSS version 24.0 for Windows, International Business Machines Corporation, Armonk, NY, USA). Differences are considered significant if the P value is <0.05.

3. Results

3.1. SAMC ameliorated hepatic injury after chronic ethanol consumption

During an 11-day of ethanol consumption, mice showed significant reduction in body weight. Daily gavage of 300 mg/kg SAMC effectively restored part of the lost body weight without affecting the weight gain in healthy mice (Fig. 1A). Of note, ethanol consumption reduced respiratory exchange ratio (RER), and energy expenditure of mice (the diet intake was manually maintained equally among groups, according to the NIAAA model guidelines). Supplementation with SAMC did not alter those parameters, implying that the body weight restorative effects might be attributed to other mechanisms, such as lipid metabolism correction and adipose tissue regulation (Supporting Information Fig. S1). As expected, the chronic-binge ethanol consumption significantly increased the liver weight, liver-to-body ratio, free fatty acids (FFAs) levels of mice, serum levels of ALT and AST which indicated a more severe status of hepatic injury, and the markedly elevated levels of TC and TG suggesting a state of dysregulated lipid metabolism. This was further validated by liver histology and TG level results (Fig. 1B–D, and G). We also demonstrate that during ALD progression, serum levels of key cytokines (TNF-α and IL-6) were also markedly elevated, indicating the occurrence of inflammation (Fig. 1E). Co-treatment with SAMC effectively ameliorated those abnormalities without changing the basal conditions. Blood ethanol level in ALD mice was reduced by SAMC (388.6 ± 18.5 vs 325.2 ± 15.7 mg/dL; P < 0.05). In addition, protein level alterations of assessed genes involved in lipid metabolism (SREBP-1C, CPT1, and ADIPOQ), ethanol/drug metabolism (ALDH2 and CYP2E1), antioxidant markers (CAT and NRF2), apoptosis (cleaved caspase-3), metabolism-related pathways (AMPK and NF-κB P65 subunit) were also reversed by SAMC co-administration during the establishment of the NIAAA model (Fig. 1F). Importantly, we compared the hepato-protective effects of SAMC with other commonly used agents (NAC, resveratrol, and silybin) on the ALD-induced liver injury model and found that SAMC had the best ameliorative effect, in terms of parameters of hepatic histology, TG, and inflammation amongst those protective agents (Supporting Information Fig. S2).
3.2. Insulin receptor signaling and adipose tissue lipolysis mediated SAMC-induced hepato-protection

Like NAFLD, chronic ethanol consumption is also able to cause insulin resistance. Thus, we examined the possible beneficial effects of SAMC co-treatment on insulin resistance. Results show that ethanol feeding induced evident insulin resistance, as suggested by impaired glucose metabolism and elevated serum insulin level. SAMC partially ameliorated the insulin resistance caused by ALD. Interestingly, vehicle SAMC administration also improved the basal insulin sensitivity of the healthy mice (Fig. 2A and B). In addition, impaired AKT (both the phosphorylated forms at Thr308 and Ser473) and GSK3β (both the phosphorylated forms at Ser9 and Tyr216) signaling was also recovered by SAMC co-treatment, when it was stimulated by insulin. Interestingly, ethanol alone reduced the phosphorylation of GSK3β, but not AKT (Fig. 2C). It should be noted that neither ethanol consumption nor SAMC treatment influenced the mRNA and protein expression levels of both Insr and insulin receptor substrate-1 (Irs-1) in the mouse liver. Induction of ALD inhibited the phosphorylation of IRS-1, which was fully restored by the co-treatment with SAMC (Supporting Information Fig. S3). To further investigate the role of insulin receptor (INSR), an AAV8-ligated Insr shRNA was injected to specifically knockdown the hepatic expression of Insr at both transcriptional and translational levels in mice, without influencing its levels in the brain, heart, white adipose tissue (WAT), and muscle (Fig. 2D). Of note, liver-specific knockdown of Insr (LIRKD) not only aggravated the ALD-induced elevation of serum chemistry, liver histology, systemic inflammation, and insulin resistance, but also significantly impaired the ameliorative effects of SAMC on those parameters (Fig. 2B–H). Importantly, there were statistically significant differences in those parameters between the ethanol and ethanol + SAMC groups in Insr deficiency mice, implying that although INSR was involved in SAMC-mediated protection, other mechanisms may also account for the amelioration of ethanol-induced injury as well.

It has been reported that chronic ethanol exposure induced adipose lipolysis and promoted hepatosteatosis. To test the contribution of adipose tissue and SAMC’s possible curative effects, we measured the changes of mass and adipocyte size of all of the three major abdominal fat depots, including epididymal, perirenal, and mesenteric white adipose tissue (WAT). Alcohol exposure significantly reduced both the mass and adipocyte size of those tissues and, as expected, co-treatment with SAMC restored the reductions (Fig. 3A and B). We also found that fatty acid released from freshly isolated epididymal WAT was markedly increased after chronic ethanol administration and alleviated by SAMC co-treatment (Fig. 3C). In addition, mice fed with ethanol exhibited upregulated adipose triglyceride lipase (ATGL) expression, increased phosphorylation level of hormone sensitive lipase (HSL), and suppressed peroxisome proliferators-activated receptors gamma (PPARγ) expression, indicating an enhanced lipolysis status. SAMC treatment significantly ameliorated such transitions (Fig. 3D). In summary, we show that insulin receptor
signaling and adipose lipolysis participated in SAMC-mediated protection against ALD. It should be noted that, since mice were still considered juvenile (7-week old) with the possible capacity to grow and malnourishment was a feature of the NIAAA feeding, thus the lack of body weight gain and increase of adipose mass could be possibly attributed to both ethanol intoxication and malnourishment.

3.3. SAMC directly targeted insulin receptor protein

To further investigate the direct interaction between SAMC and insulin receptor protein, we performed biophysical assays, TSA and SPR, by using recombinant INSR protein from a eukaryotic expression system. Results from TSA found that upon binding with SAMC, the melting temperature of INSR was elevated from \( 56 \) to \( 60 ^\circ C \) (Fig. 4A). Moreover, the SPR assay demonstrates that SAMC directly interacted with INSR in a positive dose-dependent manner (Fig. 4B). The docking prediction results reveal that SAMC compound formed three key hydrogen bonds with the residues of Arg1164, Lys1182 and Asp1183 of INSR. In addition, allylthio formed hydrophobic interaction with Le1171, Met1176, and Phe1186 residues. Previous study reported that inhibitor (S91) of the INSR targeted the catalytic binding site of the IRTK domain. Thus, we hypothesized that SAMC bound to a novel binding site of GRB14-IRTK interface to disrupt the interaction between GRB14 and IRTK (Fig. 4C and Supporting Information Fig. S4).

3.4. INSR functionally mediated SAMC-induced hepatocyte protection via modulation of insulin resistance and lipid metabolism

To further examine the role of INSR in SAMC-induced hepatocyte protection, we employed a PA and ethanol concurrent ALD-like...
AML-12 cell model. By measuring cell viability, apoptotic ratio, accumulation of lipid droplet, and caspase-3/7 activity, we observed that a 24-h co-incubation with 250 μmol/L SAMC exhibited significant improvement on chemical-induced cell damages (EC_{50} = 178.4 μmol/L for cell viability recovery, Supporting Information Fig. S5A). We also individually investigated the contribution of ethanol or PA to AML-12 damage and found that both agents could induce cell death, but could not replicate the phenotypic features of ALD mice at the same time (i.e., induction of ethanol toxicity and lipotoxicity concurrently; Fig. S5B). In line with the in vivo results, neither cell injury induction by PA/ethanol nor co-treatment with SAMC altered the mRNA and protein expressions of Insr and Irs-1 in AML-12 cells. Only the concurrent treatment with PA and ethanol reduced the phosphorylation level of IRS-1, which was then recovered by the addition of SAMC in the culture medium (Supporting Information Fig. S6). Then we transfected the siRNA of Insr, which effectively knocked-down the endogenous expression of Insr in AML-12 cells without affecting cell viability and apoptosis (Fig. 5A and B), prior to cell damage induction and SAMC co-treatment. Of note, knockdown of Insr significantly aggravated PA/ethanol-induced cell death and lipid accumulation. It also abolished the cell protective effects of SAMC (Fig. 5C and D). Indeed, deficiency of Insr impaired the insulin signaling (i.e., phosphorylation of AKT and GSK3β upon insulin stimulation) in cells, which also counter-acted the recovery effects from SAMC on insulin signaling (Fig. 5E). To further prove this finding, we characterized the insulin-mediated glucose uptake, expression changes of insulin-sensitive ADIPOQ, and lipid metabolism-related markers SREBP-1C, ACC, and CPT1 after PA/ethanol and SAMC treatments. Induction of ALD-like damage in cells significantly reduced insulin-stimulated glucose uptake, decreased ADIPOQ and CPT1 expressions, while elevated the expressions of lipid synthesis markers SREBP-1C and ACC. Although co-treatment with SAMC significantly alleviated these dysregulations, knockdown of Insr impaired the cellular protection of SAMC (Fig. 5F and G). Since we reported that SAMC could regulate NF-κB and WNT pathways, we also measured the activity changes of P65 and TCF/LEF in cells. It was exhibited that ethanol/PA promoted P65 activity but inhibited β-catenin activity, which were effectively reversed by SAMC. Deficiency of Insr potentiated the dysregulation caused by ethanol/PA, and impaired SAMC’s protection (Supporting Information Fig. S7). This finding is consistent with previous reports showing suppressed β-catenin translocation in an ALD rat model and IRS1/2 promotes WNT/β-catenin signaling by stabilizing DVL2.

To further examine the roles of insulin signaling in SAMC-mediated protection, we overexpressed Irs-1 and/or Akt before cell damage and SAMC induction in AML-12 cells. Overexpressing either or both genes did not influence AML-12 cell viability and apoptotic ratio (data not shown). It was interesting that over-expression of Akt partially restored cell functions after PA/ethanol administration (Fig. 6). Co-overexpression of Irs-1 and Akt showed better ameliorative effects than Irs-1 or Akt overexpression alone. Co-treatment with SAMC further enhanced these protective effects (Fig. 6). We also tested the function of AKT activation by IGF-1 injection in the NIAAA mice model, with or without SAMC co-treatment. As expected, activation of AKT exhibited similar alleviative effects on ethanol-induced liver injury as SAMC. Concurrent IGF-1 and SAMC exhibited the most protective outcomes (Supporting Information Fig. S8). Overall, our data indicate that insulin signaling partially contributed to SAMC-induced hepatoprotective effects against ALD.

3.5. Long-term application of SAMC was safe in healthy animals

We also checked the long-term (90-day continuous usage; 300 mg/kg, in normal saline; every other day gavage) safety of SAMC administration in healthy mice. We found no evidence of cell injury (H&E staining) in the mice liver, kidneys, spleen, and heart (Supporting Information Fig. S9A). In addition, when compared with the control group, levels of serum ALT, AST, FFA, and blood urea nitrogen (BUN) had no significant increase, implying a healthy status of these mice after long-term utilization of SAMC (Fig. S9B).

4. Discussion

Insulin resistance is a complex metabolic disorder induced by many factors such as ectopic lipid metabolites, endoplasmic...
reticulum, and innate immune activation. In the liver, ectopic lipid accumulation is one of the most important causes of insulin resistance, which mainly results in reduced glycogen synthesis/storage and a failure to suppress the production and release of glucose from the liver into the blood circulation. Inhibited INSR pathway leads to increased lipogenesis and decreased lipolysis in the liver which directly causes steatosis and subsequent inflammation. Both acute and chronic ethanol consumptions are reported to induce insulin resistance and detailed molecular mechanisms remain inadequate. Interestingly, insulin resistance triggered by NAFLD could in turn increase the blood ethanol level by an insulin-dependent impairment of alcohol dehydrogenase activity in liver tissue rather than from an increased endogenous ethanol synthesis. Application of insulin sensitizer (e.g., PPAR agonist) is shown to ameliorate hepatic insulin resistance, alcoholic steatohepatitis, and non-alcoholic steatohepatitis. A proven antioxidant and anti-inflammatory natural product, SAMC has been demonstrated to modulate the dysregulated lipid metabolism and prevent cell death in the chemical-induced liver injury and NAFLD models. Although we found that LRP6 is a direct binding receptor of SAMC in hepatoma cells, the exact regulatory mechanisms of SAMC in metabolic liver diseases are still largely unknown. By using biophysical assays, protein binding prediction and liver specific knockdown, we revealed that INSR was a direct binding receptor of SAMC on the hepatocyte membrane and SAMC could restore suppressed insulin signaling during ALD development. More importantly, concurrent supplementation with SAMC and AKT agonist IGF-1 synergistically improved the liver injury in our NIAAA model which indicated the possible involvement of the insulin signaling in ALD progression and SAMC-mediated protective effects (Fig. S8).

Currently, there is no FDA-approved specific drug agent for ALD, but several targeted treatments are under development including corticosteroids, anti-TNF antibodies, pentoxifylline, and absorbable antibiotics. Since oxidative stress is a key mechanism that drives the development of early ALD, particularly steatosis, the possibility of consuming antioxidants, either synthesized or from natural products attracts research attention. Although NAC has been suggested as the best candidate, NAC-based antioxidant therapies could not improve severe forms of alcoholic hepatitis in randomized studies. Other natural products, such as resveratrol, silymarin, and green tea-derived EGCG, were characterized as effective hepatoprotective agents against ALD. However, their targeted ‘immediate molecules’ on the cell membrane and therapeutic efficacy in ALD patients were not well studied. In the present study, SAMC was shown to possess comparable ameliorative effect, if not significantly better than those agents on cell death, oxidative stress, inflammation, and lipid dysregulation caused by chronic ethanol consumption. There might be other regulating mechanisms besides INSR binding, and our present study at least in part demonstrated the direct regulatory signaling pathway of SAMC in chronic ALD.

Admittedly, it could be shown from the results that compared the ethanol-treated Insr knockdown mice, SAMC still exhibited hepatoprotective effects (e.g., histology and inflammation) which implies the possible involvement of IR-independent pathways (e.g., CYP2E1 pathway). As a natural hepato-protective ingredient, SAMC is highly possible to regulate a number of pathways involved in hepatic ethanol intoxication, lipid metabolism, and cellular inflammation through direct interactions with targets other than insulin receptor (e.g., LRP receptors as we reported). Thus, there may be other mechanisms underlying the protection of SAMC against ALD, such as modulation of WNT signaling, as well as NF-κB and autophagy machine, as we previously reported. An unbiased membrane proteomic assay is necessary to identify novel targets of SAMC in liver cells.
Figure 5  Insulin receptor and downstream signaling mediated hepatocyte protective effect of SAMC. (A) Test of knockdown efficacy of insulin receptor (Insr) in mice normal hepatocyte line AML-12. (B) Effects of Insr knockdown on AML-12 viability and apoptotic ratio. (C) Changes of cell viability and apoptotic ratio. (D) Representative oil red O staining images. (E) Representative images and corresponding quantitative data of phosphorylated and total AKT/GSK3β (n = 3). (F) Glucose uptake ability and Adipoq mRNA. (G) Srebp-1c, Acc, and Cpt1 mRNAs when AML-12 cells were treated with cell injury induction combinations (palmitate acid + ethanol) and/or SAMC, in the absence or presence of Insr knockdown. Data are expressed as mean ± SEM (n = 4). Significant differences between the indicated groups: *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar = 50 µm.

Figure 6  Restoration of the AKT/GSK3β signaling contributed to SAMC-mediated protection in vitro. (A) Changes of cell viability, apoptotic ratio, and oil red O staining. (B) Representative oil red O staining images. (C) Changes of glucose uptake ability, Adipoq, and Srebp-1c mRNAs when AML-12 cells were treated with injury induction combination (palmitate acid + ethanol) and/or SAMC, in the absence or presence of Irs-1 and/or Akt overexpression. Data are expressed as mean ± SEM (n = 4). Significant differences between the indicated groups: *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar = 50 µm.
although we did not test the concentration of SAMC in the systemic blood flow, a previous study found that SAMC metabolized very quickly and its plasma half-life was less than 5 min in rats (one i.v. injection with 25 mg/kg SAMC, plasma level reduced from \(~400\) ng/mL at 1 min to \(~80\) ng/mL at 10 min post injection)\(^1\). A longer feeding model (e.g., 16-week alcohol feeding, or high fat + alcohol binge) might be better for ALD insulin resistance study. In conclusion, we demonstrated that aged garlic-derived SAMC was an effective treatment agent against chronic ALD-induced cell injury partly via direct binding to insulin receptor and restoration of downstream insulin signaling. Potentiation of endogenous insulin signaling, such as the IRS/AKT/GSK3\(\beta\) axis, further contributed to SAMC-mediated hepato-protective effect. To our knowledge, SAMC is the first natural product with direct insulin receptor binding and insulin signaling restoration properties identified by our study. Since long-term administration of SAMC had no detectable adverse effects on healthy mice, we propose that it might be considered an alternative agent for ALD treatment and it could also be explored for future clinical applications and research. Future studies on human cognitive impairments are also warranted.

Acknowledgments

This work was supported by National Natural Science Foundation of China (81970515) and Guangdong Natural Science Funds for Distinguished Young Scholar (2019B151502013, China).

Author contributions

Jia Xiao and George L. Tipoe conceived the study, designed the experiments, and wrote the manuscript. Pingping Luo, Ming Zheng, Rui Zhang, Xiaoming Sun, Wei Li and Qian Yu performed the experiments. Hong Zhang and Yingxia Liu analyzed the data and edited the manuscript. All authors approved the final version of the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.appb.2020.11.006.

References

1. Louvet A, Mathurin P. Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015;12: 231–42.
2. Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol 2019;71:212–21.
3. Liangpunsakul S, Haber P, McCaughan GW. Alcoholic liver disease in Asia, Europe, and North America. Gastroenterology 2016;150: 1786–97.
4. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018;4:16.
5. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: Results from population-based surveillance. J Clin Gastroenterol 2010;44:301–7.
6. He J, de la Monte S, Wands JR Wands. Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology 2007;46:1791–800.
7. de la Monte S, Derdak Z, Wands JR. Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol 2012;27 Suppl 2: 33–41.
8. Inoue H. Central insulin-mediated regulation of hepatic glucose production. Endocr J 2016;63:1–7.
9. Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011;46: 200–15.
10. He L, Simmen FA, Mehendele HM, Ronis MJ, Badger TM. Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J Biol Chem 2006;281:11126–34.
11. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009;50: 1192–201.
12. Zhu X, Jiang X, Li A, Sun Y, Liu Y, Sun X, et al. S-Allylmercaptocysteine suppresses the growth of human gastric cancer xenografts through induction of apoptosis and regulation of PI3K/Akt signaling pathways. Biochem Biophys Res Commun 2017; 491:821–6.
13. Li S, Yang G, Zhu X, Cheng L, Sun Y, Zhao Z. Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy/p62/Nrf2 pathway. Oncol Rep 2017;38: 1637–44.
14. Howard EW, Ling MT, Chua CW, Cheung HW, Wang X, Wong YC. Garlic-derived S-allylmercaptocysteine is a novel in vivo anti-metastatic agent for androgen-independent prostate cancer. Clin Canc Res 2007;13:1847–56.
15. Wu J, Zhao S, Zhang J, Qu X, Jiang S, Zhong Z, et al. Over-expression of survivin is a factor responsible for differential responses of ovarian cancer cells to S-allylmercaptocysteine (SAMC). Exp Mol Pathol 2016;100:294–302.
16. Liu Y, Yan J, Han X, Hu W. Garlic-derived compound S-allylmercaptocysteine (SAMC) is active against anaplastic thyroid cancer cell line 8050C (HPACC). Technol Health Care 2015;23 Suppl 1:889–93.
17. Xiao J, Liong EC, Ling MT, Ching YP, Fung ML, Tipoe GL. S-Allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice. Eur J Nutr 2012;51:323–33.
18. Xiao J, Ching YP, Liong EC, Nanji AA, Fung ML, Tipoe GL. Garlic-derived S-allylmercaptocysteine is a hepatoprotective agent in non-alcoholic fatty liver disease in vivo animal model. Eur J Nutr 2013; 52:179–91.
19. Xiao J, Guo R, Fung ML, Liong EC, Chang RC, Ching YP, et al. Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat model through inhibition of apoptosis and enhancing autophagy. Evid Based Complement Alternat Med 2013; 2013:642920.
20. Xiao J, Xing F, Liu Y, Lv Y, Wang X, Ling MT, et al. Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRPT/Wnt pathway. Acta Pharm Sin B 2018;8: 575–86.
21. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2008;3: 827–37.
22. Zeng T, Zhang CL, Zhao N, Guan MJ, Xiao M, Yang R, et al. Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver. Redox Biol 2018;14: 295–304.
23. Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008;49:1019–28.
24. Schämming J, Prockl J, Kiener AK, Vollmar AM, Bang R, Tieg G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39:333–40.

25. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 2011;53:810–20.

26. Solon-Biet SM, Mitchell SJ, Coogan SC, Cogger VC, Gokarn R, McMahon AC, et al. Dietary protein to carbohydrate ratio and caloric restriction: Comparing metabolic outcomes in mice. Cell Rep 2015;11:1529–34.

27. Depetris RS, Hu J, Gimpelevich I, Holt LJ, Daly RJ, Hubbard SR. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell 2005;20:325–33.

28. Gondoin A, Hampe C, Eudes R, Fayolle C, Pierre-Eugène C, Katayama N, Orita M, Yamaguchi T, Hisamichi H, Kuromitsu S, Wang F, Tipoe GL, Yang C, Nanji AA, Hao X, So KF, et al. Peroxisome proliferator-activated receptor agonist against treatment of alcohol-induced hepatic insulin resistance. Hepatol Res 2011;41:386–98.

29. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial. J Hepatol 2008;49:784–90.

30. Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial. J Hepatol 2010;53:1117–22.

31. Luo G, Huang B, Qiu X, Xiao L, Wang N, Gao Q, et al. Resveratrol attenuates excessive ethanol exposure induced insulin resistance in rats via improving NAD+/NADH ratio. Mol Nutr Food Res 2017;61:1700087.

32. Testino G, Leone S, Ansaldi F, Borro P. Silimarina and S-adenosyl-L-methionine (SAmE): Two promising pharmacological agents in case of chronic alcoholic hepatoathpy. A review and a point of view. Minerva Gastroenterol Dietol 2013;59:341–56.

33. Luo P, Wang F, Wong NK, Lv Y, Li X, Li M, et al. Divergent roles of kupffer cell TLR2/3 signaling in alcoholic liver disease and the protective role of EGCG. Cell Mol Gastroenterol Hepatol 2020;9:145–60.

34. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial. J Hepatol 2008;49:784–90.

35. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial. J Hepatol 2008;49:784–90.

36. Schrieks IC, Heil AL, Hendriks HF, Mukamal KJ, Beulens JW. The effect of alcohol consumption on insulin sensitivity and glycemic status: A systematic review and meta-analysis of intervention studies. Diabetes Care 2015;38:723–32.

37. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77–86.